How to Start a
Peptide Clinic

What Is a Peptide Clinic?

Peptide clinics may address weight management, hormone-related concerns, sexual health, recovery, or other clinical goals through a medical evaluation, laboratory review when indicated, prescribing, education, and follow-up. Compounds commonly discussed in the market include BPC-157, TB-500, CJC-1295, Ipamorelin, PT-141, Sermorelin, and semaglutide, but a marketing list is not a compliance analysis.

Each compound, route, source, intended use, and patient population needs its own assessment. A responsible practice documents medical necessity or the clinical rationale, contraindications, alternatives, risks, and monitoring rather than relying on a generic wellness questionnaire.

The operating model may be telehealth-first, in-person, or hybrid. In every case, the patient location, prescriber authority, state rules, and privacy controls shape the workflow.

Entity Structure, CPOM, and Medical Director

Corporate practice of medicine rules can restrict non-physician ownership and clinical control. A compliant structure may use a physician-owned professional entity for medical services and a management services organization for administrative support. The model must be tailored to the states where patients receive care.

The medical director should approve protocols, oversee clinician onboarding, set consultation and lab thresholds, review adverse events, conduct quality audits, and supervise or collaborate with NPs and PAs where state law requires it. Clinical authority cannot be reduced to a title on a website.

Non-clinical leaders can manage operations, technology, scheduling, finance, and reviewed marketing. They should not dictate prescription eligibility, compel clinicians to use a specific compound, or make medical decisions based on revenue goals.

FDA Landscape, Compounding, and Product Selection

FDA regulation of peptide products is dynamic. A clinic should not infer that a compound may be compounded, marketed, or prescribed simply because it appears on an online menu. The FDA bulk drug substance framework, drug shortages, approved-product availability, and pharmacy-specific practices can all affect what is permissible.

503A pharmacies compound pursuant to valid patient-specific prescriptions. They are not a shortcut around approval requirements, and compounded products should not be represented as FDA approved. Vet the pharmacy's licenses, state service footprint, sterile compounding controls, quality systems, complaint history, shipping, and ability to support the precise medication workflow.

Create a product-review committee or physician-led review process. Keep current documentation of the compound, source, clinical rationale, known restrictions, patient information, and decision to add, pause, or remove it from protocols.

• ✓Review current FDA communications, bulk substance status, and enforcement developments before adding a compound.
• ✓Use licensed pharmacy partners with documented patient-specific prescription processes.
• ✓Do not imply that a compounded peptide is FDA approved or equivalent to an approved product.
• ✓Maintain an approved-product list that is reviewed and updated by clinical leadership.

Licensing, Credentialing, and Prescribing Authority

The clinician generally needs authority to practice where the patient is located at the time of service. Physicians, NPs, and PAs may have different independent-practice, collaboration, supervision, prescribing, and telehealth obligations in each jurisdiction. Credential each clinician before launch and monitor renewals, exclusions, training, and scope changes.

For insurance-billed services, complete payer credentialing and enrollment as required, including CAQH profile maintenance, PECOS enrollment for Medicare participation, and Medicaid enrollment where applicable. A cash-pay model still requires reliable clinical records and identity verification.

DEA registration may be relevant if a prescriber orders a controlled substance associated with the clinic's services. Review each medication and state registration requirement rather than assuming the word peptide answers the question.

Clinical Documentation, Consent, and Lab Monitoring

Off-label prescribing can be lawful when supported by a clinician's professional judgment, but it requires more than a prewritten script. The record should explain why the therapy is being considered for that patient, what alternatives were discussed, how the patient was screened, and what follow-up is planned.

Informed consent should be specific to the compound and clinical context. It should address known and material risks, uncertainties, adverse-event instructions, product status where relevant, alternatives, and the possibility that a plan may be changed or stopped. For investigational or uncertain compounds, clarity is essential.

Medical leadership should establish baseline and follow-up lab protocols where clinically indicated, including thresholds for treatment holds, dose changes, urgent review, or specialist referral.

• ✓Use a patient-specific history, eligibility review, and documented clinical rationale.
• ✓Obtain compound-specific informed consent with risks, alternatives, and uncertainty.
• ✓Set physician-approved baseline and follow-up lab rules where clinically indicated.
• ✓Document dose changes, missed monitoring, adverse events, referrals, and treatment holds.

HIPAA, OSHA, Technology, and Pharmacy Workflows

Use a HIPAA-compliant EMR, secure patient messaging, role-based access, business associate agreements, privacy training, and incident response procedures. Telehealth workflows should capture patient identity and physical location, clinician authority, consent, and emergency escalation information.

In-person clinics also need OSHA bloodborne pathogen, sharps, exposure-control, PPE, medication-storage, and infection-control processes. If the clinic performs testing, assess CLIA requirements before relying on point-of-care or laboratory workflows.

Pharmacy operations should define prescribing, refill review, patient address verification, shipping exceptions, complaints, recalls, and adverse-event escalation. A pharmacy relationship is not a transfer of the clinic's duty to supervise its own clinical process.

Startup Costs, Staffing, and Revenue Cycle

A telehealth-focused peptide clinic may require less facility investment than a procedure-based practice, but it still needs capital for compliant entities, medical direction, multi-state licensing, EMR and telehealth technology, cybersecurity, clinical operations, insurance, pharmacy and lab integration, and acquisition. In-person operations add leasehold, staffing, equipment, and inventory expense.

Staffing often includes a medical director, treating physicians or advanced-practice clinicians, care coordinators, patient support, billing personnel where insurance is used, and compliance or operations support. Match staff roles to scope and patient complexity.

Many peptide programs use cash-pay memberships or per-visit pricing. Make included services, medication costs, labs, renewals, cancellations, and refunds clear. If billing plans, establish coding, documentation, claims, denial, and audit processes before submission.

Marketing and Patient Acquisition

Do not promise disease cures, dramatic body transformation, permanent results, or risk-free treatment. FDA and FTC standards, state professional rules, and advertising-platform policies can all apply. Claims about BPC-157, TB-500, weight loss, sexual health, longevity, recovery, or metabolic outcomes require particular caution.

Build acquisition around accurate education: what an evaluation involves, why labs or monitoring may be needed, how clinician eligibility is determined, and what follow-up looks like. Review landing pages, call scripts, search ads, testimonials, affiliates, and social content before publication.

Track lead quality, booked consultations, appropriate activation, monitoring completion, patient complaints, and acquisition cost. Do not give sales staff authority to make clinical assurances or promise a prescription.

• ✓Avoid cure, guaranteed-outcome, and unsupported safety claims.
• ✓Do not state or imply FDA approval for compounded products.
• ✓Require clinical and legal review of ads, scripts, testimonials, and influencer content.
• ✓Train staff to describe evaluation and eligibility without promising treatment.

Compliance and Risk Management

Current FDA enforcement actions and communications should be monitored as part of governance, not as an occasional internet search. Assign a responsible clinician or compliance owner to review developments, assess protocols, and document whether a product or claim needs to change.

Review malpractice coverage for the actual services, states, telehealth model, and compounds offered. Maintain incident reporting, patient complaint handling, adverse-event escalation, and corrective-action records.

Audit charts for clinical rationale, consent, lab adherence, prescribing, refills, follow-up, and referral triggers. Audit suppliers, marketing, access logs, and training on a defined cadence.

• ✓Monitor regulatory changes and documented enforcement developments.
• ✓Confirm malpractice coverage for actual services, patient locations, and practice modality.
• ✓Audit charts, refill workflows, supplier files, privacy controls, and marketing regularly.
• ✓Document corrective action, retraining, protocol revisions, and medical-director review.